DK2242840T3 - Produktion af rekombinant adeno-associeret virus under anvendelse af bhk-celler i suspension - Google Patents
Produktion af rekombinant adeno-associeret virus under anvendelse af bhk-celler i suspension Download PDFInfo
- Publication number
- DK2242840T3 DK2242840T3 DK09706778.9T DK09706778T DK2242840T3 DK 2242840 T3 DK2242840 T3 DK 2242840T3 DK 09706778 T DK09706778 T DK 09706778T DK 2242840 T3 DK2242840 T3 DK 2242840T3
- Authority
- DK
- Denmark
- Prior art keywords
- suspension
- manufacture
- associated viruses
- bhk cells
- recombinant adeno
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000000725 suspension Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
- C12N15/8645—Adeno-associated virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16661—Methods of inactivation or attenuation
- C12N2710/16662—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/50—Vectors for producing vectors
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6281908P | 2008-01-29 | 2008-01-29 | |
| PCT/US2009/000577 WO2009097129A1 (en) | 2008-01-29 | 2009-01-29 | Recombinant virus production using mammalian cells in suspension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2242840T3 true DK2242840T3 (da) | 2019-10-21 |
Family
ID=40913147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09706778.9T DK2242840T3 (da) | 2008-01-29 | 2009-01-29 | Produktion af rekombinant adeno-associeret virus under anvendelse af bhk-celler i suspension |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20110229971A1 (da) |
| EP (1) | EP2242840B1 (da) |
| AU (1) | AU2009209408B2 (da) |
| CA (1) | CA2713338C (da) |
| DK (1) | DK2242840T3 (da) |
| ES (1) | ES2751999T3 (da) |
| WO (1) | WO2009097129A1 (da) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3591055A1 (en) * | 2011-01-07 | 2020-01-08 | Applied Genetic Technologies Corporation | Promoters derived from the 5' nontranslated region (5'-ntr) of the human cyclic nucleotide gated beta 3 (cngb3) gene, expression cassettes and vectors comprising said promoters, for use treating achromatopsia and other diseases |
| GB201103062D0 (en) | 2011-02-22 | 2011-04-06 | Isis Innovation | Method |
| ES2702496T3 (es) * | 2011-04-21 | 2019-03-01 | Nationwide Childrens Hospital Inc | Productos de virus recombinante y procedimientos para la inhibición de la expresión de la miotilina |
| US10196636B2 (en) | 2011-04-21 | 2019-02-05 | Nationwide Children's Hospital, Inc. | Recombinant virus products and methods for inhibition of expression of myotilin |
| CN105377039A (zh) | 2013-05-15 | 2016-03-02 | 明尼苏达大学董事会 | 腺相关病毒介导的基因向中枢神经系统转移 |
| WO2015081101A1 (en) | 2013-11-26 | 2015-06-04 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Adeno-associated virus vectors for treatment of glycogen storage disease |
| CA2945965C (en) * | 2014-04-15 | 2022-11-01 | Applied Genetic Technologies Corporation | Codon optimized nucleic acid encoding a retinitis pigmentosa gtpase regulator (rpgr) |
| WO2015191508A1 (en) | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Chimeric capsids |
| GB201417042D0 (en) * | 2014-09-29 | 2014-11-12 | Fkd Therapies Oy | Method |
| SG11201703148TA (en) | 2014-11-05 | 2017-05-30 | Voyager Therapeutics Inc | Aadc polynucleotides for the treatment of parkinson's disease |
| WO2016073900A1 (en) * | 2014-11-06 | 2016-05-12 | Case Western Reserve University | Compositions and methods of treating usher syndrome iii |
| CN119876138A (zh) | 2014-11-14 | 2025-04-25 | 沃雅戈治疗公司 | 调节性多核苷酸 |
| CA3193811A1 (en) | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| CA2969145A1 (en) * | 2014-11-26 | 2016-06-02 | The Regents Of The University Of California | Therapeutic compositions comprising transcription factors and methods of making and using the same |
| HK1245326A1 (zh) | 2014-12-12 | 2018-08-24 | Voyager Therapeutics, Inc. | 用於生产scaav的组合物和方法 |
| JP6824169B2 (ja) | 2014-12-23 | 2021-02-03 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 改変ｇ６ｐｃをコードするアデノ随伴ウイルスベクターおよびその使用 |
| IL286316B2 (en) | 2015-01-16 | 2023-03-01 | Univ Washington | New micro-dystrophins and related method of use |
| AU2016228751B2 (en) | 2015-03-11 | 2022-01-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Rp2 vectors for treating x-linked retinitis pigmentosa |
| CN115074366A (zh) | 2015-04-16 | 2022-09-20 | 埃默里大学 | 用于肝脏中蛋白质表达的重组启动子和载体及其用途 |
| CA2983808C (en) | 2015-04-23 | 2022-03-22 | Washington State University | Smad7 gene delivery as a therapeutic |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| DK3365438T3 (da) | 2015-10-21 | 2021-07-12 | Us Health | Codon-optimeret reduceret-størrelse atp7a cdna og anvendelser ved behandling af kobbertransportlidelser |
| US20180230489A1 (en) | 2015-10-28 | 2018-08-16 | Voyager Therapeutics, Inc. | Regulatable expression using adeno-associated virus (aav) |
| PL3411484T3 (pl) | 2016-02-05 | 2024-02-19 | Emory University | Wstrzykiwanie jednoniciowego lub samokomplementarnego wirusa adenosatelitarnego 9 do płynu mózgowego |
| EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| CA3024448C (en) | 2016-05-18 | 2025-09-09 | Voyager Therapeutics, Inc. | MODULATING POLYNUCLEOTIDES |
| CA3024449A1 (en) | 2016-05-18 | 2017-11-23 | Voyager Therapeutics, Inc. | Compositions and methods of treating huntington's disease |
| WO2018044933A1 (en) | 2016-08-30 | 2018-03-08 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
| AU2018212002A1 (en) | 2017-01-30 | 2019-08-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant virus vectors for the treatment of glycogen storage disease |
| JP2020518259A (ja) | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ハンチントン病治療組成物および方法 |
| EP3618839A4 (en) | 2017-05-05 | 2021-06-09 | Voyager Therapeutics, Inc. | COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| EP3622065A1 (en) | 2017-05-09 | 2020-03-18 | Emory University | Clotting factor variants and their use |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| JP7229989B2 (ja) | 2017-07-17 | 2023-02-28 | ボイジャー セラピューティクス インコーポレイテッド | 軌道アレイガイドシステム |
| TWI835747B (zh) | 2017-09-22 | 2024-03-21 | 賓州大學委員會 | 用於治療黏多醣病 ii 型之基因治療 |
| US20200263199A1 (en) | 2017-09-29 | 2020-08-20 | Voyager Therapeutics, Inc. | Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery |
| WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| TW202413649A (zh) | 2017-10-16 | 2024-04-01 | 美商航海家醫療公司 | 肌萎縮性脊髓側索硬化症(als)之治療 |
| WO2019169291A1 (en) | 2018-03-02 | 2019-09-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of il-34 to treat retinal inflammation and neurodegeneration |
| WO2019212922A1 (en) | 2018-04-29 | 2019-11-07 | Regenxbio Inc. | Systems and methods of spectrophotometry for the determination of genome content, capsid content and full/empty ratios of adeno-associated virus particles |
| WO2019212921A1 (en) | 2018-04-29 | 2019-11-07 | Regenxbio Inc. | Scalable clarification process for recombinant aav production |
| SG11202011296VA (en) | 2018-05-15 | 2020-12-30 | Voyager Therapeutics Inc | Compositions and methods for the treatment of parkinson's disease |
| WO2019241535A2 (en) | 2018-06-14 | 2019-12-19 | Regenxbio Inc. | Anion exchange chromatography for recombinant aav production |
| US20210254103A1 (en) | 2018-07-02 | 2021-08-19 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord |
| CN110699367B (zh) * | 2018-07-09 | 2021-06-11 | 武汉纽福斯生物科技有限公司 | 编码人nadh脱氢酶亚单位4蛋白的核酸及其应用 |
| AU2019310459A1 (en) | 2018-07-24 | 2021-02-18 | Voyager Therapeutics, Inc. | Systems and methods for producing gene therapy formulations |
| EP3833745A1 (en) | 2018-08-10 | 2021-06-16 | REGENXBIO Inc. | Scalable method for recombinant aav production |
| US12281321B2 (en) | 2018-09-28 | 2025-04-22 | Voyager Therapeutics, Inc. | Frataxin expression constructs having engineered promoters and methods of use thereof |
| WO2020072849A1 (en) | 2018-10-04 | 2020-04-09 | Voyager Therapeutics, Inc. | Methods for measuring the titer and potency of viral vector particles |
| JP2022514112A (ja) | 2018-10-15 | 2022-02-09 | リジェネクスバイオ インコーポレイテッド | 複製欠損型ウイルスベクター及びウイルスの感染性を測定するための方法 |
| ES2969222T3 (es) | 2018-12-18 | 2024-05-17 | Ultragenyx Pharmaceutical Inc | Métodos y composiciones para el tratamiento de enfermedades del almacenamiento de glucógeno |
| KR20210112339A (ko) | 2019-01-04 | 2021-09-14 | 울트라제닉스 파마수티컬 인코포레이티드 | 윌슨병을 치료하기 위한 유전자 요법 구축물 |
| JP2022522995A (ja) | 2019-01-18 | 2022-04-21 | ボイジャー セラピューティクス インコーポレイテッド | Ａａｖ粒子を生成するための方法及びシステム |
| WO2020163703A1 (en) | 2019-02-08 | 2020-08-13 | Krystal Biotech, Inc. | Compositions and methods for delivering cftr polypeptides |
| US20220098614A1 (en) | 2019-02-28 | 2022-03-31 | Benitec IP Holdings Inc. | Compositions and Methods for Treating Oculopharyngeal Muscular Dystrophy (OPMD) |
| HUE064411T2 (hu) | 2019-04-11 | 2024-03-28 | Regenxbio Inc | Méretkizárásos kromatográfiás módszerek rekombináns adeno-asszociált víruskészítmények jellemzésére |
| US20220143115A1 (en) | 2019-04-19 | 2022-05-12 | Regenxbio Inc. | Adeno-Associated Virus Vector Formulations and Methods |
| EP3962536A1 (en) | 2019-04-29 | 2022-03-09 | Voyager Therapeutics, Inc. | Systems and methods for producing baculoviral infected insect cells (biics) in bioreactors |
| WO2021030125A1 (en) | 2019-08-09 | 2021-02-18 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
| TW202122582A (zh) | 2019-08-26 | 2021-06-16 | 美商航海家醫療公司 | 病毒蛋白之控制表現 |
| WO2021062012A1 (en) | 2019-09-25 | 2021-04-01 | Emory University | Use of klk10 and engineered derivatizations thereof |
| US20210189427A1 (en) * | 2019-12-20 | 2021-06-24 | Krystal Biotech, Inc. | Compositions and methods for gene delivery to the airways and/or lungs |
| JP7703543B2 (ja) | 2020-01-17 | 2025-07-07 | ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Ｃｒｘ常染色体優性網膜症の処置のための遺伝子治療 |
| MX2022009982A (es) | 2020-02-14 | 2022-09-12 | Ultragenyx Pharmaceutical Inc | Terapia genica para el tratamiento de transtorno por deficiencia de cdkl5. |
| WO2022032153A1 (en) | 2020-08-06 | 2022-02-10 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
| CN112107696A (zh) * | 2020-09-14 | 2020-12-22 | 台州和和生物科技有限公司 | 一种创新性的特殊途径给药的基因治疗药物及其药盒 |
| WO2022061002A1 (en) | 2020-09-18 | 2022-03-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Novel adeno-associated viral (aav) vectors to treat hereditary methylmalonic acidemia (mma) caused by methylmalonyl-coa mutase (mmut) deficiency |
| EP4263841A1 (en) | 2020-12-16 | 2023-10-25 | REGENXBIO Inc. | Method of producing a recombinant adeno-associated virus particle |
| EP4281568A1 (en) | 2021-01-21 | 2023-11-29 | RegenxBio Inc. | Improved production of recombinant polypeptides and viruses |
| US20240141378A1 (en) | 2021-03-03 | 2024-05-02 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| US20240141377A1 (en) | 2021-03-03 | 2024-05-02 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| EP4322975A4 (en) * | 2021-04-14 | 2025-03-26 | Capsida, Inc. | PLASMIDS AND PROCESSES FOR PRODUCING ADENO-ASSOCIATED VIRUSES |
| KR20240095165A (ko) | 2021-08-11 | 2024-06-25 | 솔리드 바이오사이언시즈 인크. | 근이영양증의 치료 |
| CN115873987A (zh) * | 2021-09-30 | 2023-03-31 | 北京五加和基因科技有限公司 | 检测腺相关病毒载体感染滴度的方法和试剂盒 |
| CN118202060A (zh) | 2021-10-05 | 2024-06-14 | 再生生物股份有限公司 | 用于重组aav生产的组合物和方法 |
| WO2023060113A1 (en) | 2021-10-05 | 2023-04-13 | Regenxbio Inc. | Compositions and methods for recombinant aav production |
| WO2023114816A1 (en) | 2021-12-14 | 2023-06-22 | Neurogene, Inc. | Recombinant optimized galc constructs and methods for treating galc-associated disorders |
| GB202201242D0 (en) | 2022-01-31 | 2022-03-16 | Univ Edinburgh | Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders |
| WO2023183623A1 (en) | 2022-03-25 | 2023-09-28 | Regenxbio Inc. | Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy |
| WO2023196898A1 (en) | 2022-04-07 | 2023-10-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Beta globin mimetic peptides and their use |
| GB202206336D0 (en) | 2022-04-29 | 2022-06-15 | Univ Edinburgh | Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders |
| WO2023239627A2 (en) | 2022-06-08 | 2023-12-14 | Regenxbio Inc. | Methods for recombinant aav production |
| US20260085328A1 (en) | 2022-09-08 | 2026-03-26 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| WO2024168358A1 (en) | 2023-02-10 | 2024-08-15 | Expression Therapeutics, Llc | Lentiviral system |
| JP2026508221A (ja) | 2023-02-22 | 2026-03-10 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 免疫優性ｔ細胞エピトープを欠く組換えアデノ随伴ウイルスベクターおよびその使用 |
| AU2024240009A1 (en) | 2023-03-17 | 2025-09-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for treatment of age-related macular degeneration |
| WO2024211780A1 (en) | 2023-04-07 | 2024-10-10 | Regenxbio Inc. | Compositions and methods for recombinant aav production |
| EP4709866A2 (en) | 2023-05-07 | 2026-03-18 | REGENXBIO Inc. | Compositions and methods for recombinant aav production |
| WO2025090962A1 (en) | 2023-10-25 | 2025-05-01 | Regenxbio Inc. | Compositions and methods for recombinant aav production |
| WO2025106374A1 (en) | 2023-11-13 | 2025-05-22 | Juno Therapeutics, Inc. | Aav production method |
| WO2026017965A1 (en) | 2024-07-19 | 2026-01-22 | The University Court Of The University Of Edinburgh | Recombinant therapeutic fxn constructs and methods of treating friedreich ataxia and related conditions |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6686200B1 (en) * | 1993-08-31 | 2004-02-03 | Uab Research Foundation | Methods and compositions for the large scale production of recombinant adeno-associated virus |
| DE4438833A1 (de) * | 1994-10-31 | 1996-05-02 | Bayer Ag | Verfahren zur analytischen Trennung von Viren |
| DE19830141A1 (de) * | 1998-07-06 | 2000-01-13 | Regine Heilbronn | Rekombinante Herpesviren für die Erzeugung rekombinanter Adeno-Assoziierter-Viren |
| US6793926B1 (en) * | 1999-05-27 | 2004-09-21 | Genovo, Inc. | Methods for production of a recombinant adeno-associated virus |
| GB2375479B (en) * | 2002-02-23 | 2003-03-26 | Beldore Ltd | Waste water outlet unit |
| US20070202587A1 (en) * | 2002-09-23 | 2007-08-30 | Applied Genetic Technologies Corporation | Recombinant AAV production in mammalian cells |
| US7091029B2 (en) | 2002-09-23 | 2006-08-15 | Applied Genetics Technologies Corporation | High titer recombinant AAV production |
| WO2007059473A2 (en) | 2005-11-12 | 2007-05-24 | Introgen Therapeutics, Inc. | Methods for the production and purification of adenoviral vectors |
| US20110014232A1 (en) * | 2009-07-16 | 2011-01-20 | Agricultural Research Council | Chimeric foot and mouth disease viruses |
-
2009
- 2009-01-29 DK DK09706778.9T patent/DK2242840T3/da active
- 2009-01-29 ES ES09706778T patent/ES2751999T3/es active Active
- 2009-01-29 WO PCT/US2009/000577 patent/WO2009097129A1/en not_active Ceased
- 2009-01-29 AU AU2009209408A patent/AU2009209408B2/en not_active Ceased
- 2009-01-29 EP EP09706778.9A patent/EP2242840B1/en active Active
- 2009-01-29 CA CA2713338A patent/CA2713338C/en active Active
-
2010
- 2010-07-13 US US12/812,671 patent/US20110229971A1/en not_active Abandoned
-
2012
- 2012-11-21 US US13/683,577 patent/US9783826B2/en active Active
-
2017
- 2017-09-07 US US15/697,655 patent/US20180312872A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009097129A1 (en) | 2009-08-06 |
| US20180312872A1 (en) | 2018-11-01 |
| AU2009209408A1 (en) | 2009-08-06 |
| CA2713338C (en) | 2021-10-26 |
| EP2242840A1 (en) | 2010-10-27 |
| AU2009209408B2 (en) | 2015-06-11 |
| US20110229971A1 (en) | 2011-09-22 |
| US9783826B2 (en) | 2017-10-10 |
| US20130244331A1 (en) | 2013-09-19 |
| EP2242840A4 (en) | 2012-12-19 |
| ES2751999T3 (es) | 2020-04-02 |
| CA2713338A1 (en) | 2009-08-06 |
| EP2242840B1 (en) | 2019-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2242840T3 (da) | Produktion af rekombinant adeno-associeret virus under anvendelse af bhk-celler i suspension | |
| EP2198016A4 (en) | ADENO ASSOCIATED SWINE VIRUS | |
| DK2375907T3 (da) | Behandling af sygdomme, lidelser eller tilstande i lungerne under anvendelse af placentaceller | |
| DK3064508T4 (da) | Fremgangsmåde til fremstilling af rekombinant vwf med høj molekylevægt i cellekultur | |
| DK2279263T3 (da) | Rnase-h-baserede assays med anvendelse af modificerede rna-monomerer | |
| DK3287525T3 (da) | RNA-præparater omfattende oprenset modificeret RNA til omprogrammering af celler | |
| EP2240973A4 (en) | POROUS ELECTRODES AND CORRESPONDING METHODS | |
| DK2272119T3 (da) | Elektrodeseparator | |
| ITFO20080002A1 (it) | Pale rotoriche e statoriche con lean sinusoidale | |
| LT2699270T (lt) | Adeno-asocijuoto viruso virionai su variantine kapside ir jų naudojimo būdai | |
| DK2349314T3 (da) | Lyofiliserede præparater af rekombinant VWF | |
| BRPI0922912A2 (pt) | peptídeos de 4-amino-4-oxobutanoil como inibidores de replicação viral | |
| DK1976516T3 (da) | Behandling af viral hepatitis | |
| EP2516381A4 (en) | ETHERAMINES AND THEIR USE AS INTERMEDIATE PRODUCTS IN POLYMER SYNTHESIS | |
| DK2841606T3 (da) | Fusionsproteiner til at lette selektionen af celler inficeret med specifikt immunoglobulingenrekombinant vacciniavirus | |
| EP2234624A4 (en) | NEW VACCINES AGAINST SEVERAL SUBTYPES OF THE DENGUE VIRUS | |
| DK2744456T3 (da) | Forbedringer ved eller i forbindelse med proteser og ortoser | |
| DK2171457T3 (da) | Forbedringer i eller vedrørende fremstilling af konjugater | |
| DK2512225T3 (da) | Anvendelse af vip3ab i kombination med cry1ca til bekæmpelse af resiste insekter | |
| EP2576581A4 (en) | RECOMBINANT RNA VIRUSES AND USES THEREOF | |
| DK2297054T3 (da) | Fremgangsmåde til fremstilling af cellulære keramiske plader med asymmetrisk cellestruktur | |
| EP2307047A4 (en) | RESPIRATORY SYNCYTIAL VIRUS MAKES TOLEROGENIC DENDRITIC CELLS | |
| DK1928643T3 (da) | Fremgangsmåde til fremstilling af kompositelementer med forøget styrke | |
| DK2349341T3 (da) | Pegylering af rekombinante blodkoagulationsfaktorer i nærvær af bundne antistoffer | |
| DK2379995T3 (da) | Vejecelle |